Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Hans M. L. Spiegel"'
Autor:
Joseph A Politch, Susan Cu-Uvin, Thomas R Moench, Karen T Tashima, Jai G Marathe, Kate M Guthrie, Howard Cabral, Tara Nyhuis, Miles Brennan, Larry Zeitlin, Hans M L Spiegel, Kenneth H Mayer, Kevin J Whaley, Deborah J Anderson
Publikováno v:
PLoS Medicine, Vol 18, Iss 2, p e1003495 (2021)
BackgroundMB66 film is a multipurpose prevention technology (MPT) product with monoclonal antibodies (mAbs) against HIV-1 (VRC01-N) and HSV-1 and 2 (HSV8-N). The mAbs were produced by transient expression in Nicotiana benthamiana (N). We conducted a
Externí odkaz:
https://doaj.org/article/080a0cd6780b4946ae5836420c4ae97a
Autor:
Sharon L. Achilles, Peter A. Anton, Nicola Richardson-Harman, Ross D Cranston, Jarret Engstrom, Kaleab Z. Abebe, Sylvain Chawki, Hans M. L. Spiegel, Beatrice A. Chen, Craig W. Hendrix, Cindy Jacobson, Aaron Siegel, Mark A. Marzinke, Lisa C. Rohan, Alex Reinhart, John Steytler, Ron Stall, Elena Khanukova, Ian McGowan, Rhonda M. Brand
Publikováno v:
AIDS Res Hum Retroviruses
The Combination HIV Antiretroviral Rectal Microbicide-3 (CHARM-03) study was a randomized, open-label, crossover Phase 1 safety and pharmacokinetic (PK) study of oral maraviroc (MVC) and MVC 1% gel. At a single site, healthy HIV-uninfected men and wo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e017b88cd60d3a0ac5b2b8db7cf5512
https://pubmed.ncbi.nlm.nih.gov/34384282
https://pubmed.ncbi.nlm.nih.gov/34384282
Autor:
Hans M. L. Spiegel, Andrew G. Allmon, Humphrey Mwape, Carla J. Chibwesha, Chipepo Kankasa, Mildred Lusaka, Benjamin H. Chi, Katie R. Mollan, Emmanuel Mweni, Felistas Mbewe, Aaron Shibemba, Rose Lungu, Jeffrey S. A. Stringer, Pooja T. Saha, Catherine E. Ford
Publikováno v:
Clinical Infectious Diseases. 75:260-268
Background Point-of-care (POC) early infant diagnosis (EID) provides same-day results and the potential for immediate initiation of antiretroviral therapy (ART). Methods We conducted a pragmatic trial at 6 public clinics in Zambia. HIV-exposed infant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98e1f07dd163eca31ec28921df711383
https://doi.org/10.1093/cid/ciab923
https://doi.org/10.1093/cid/ciab923
Autor:
Allison L Agwu, Meredith G Warshaw, Elizabeth J McFarland, George K Siberry, Ann J Melvin, Andrew A Wiznia, Lee Fairlie, Sandra Boyd, Paul Harding, Hans M L Spiegel, Elaine J Abrams, Vincent J Carey, P1094 Study Team
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0178075 (2017)
INTRODUCTION:Management of persistently non-adherent youth living with HIV (YLHIV) with virologic failure (VF) on combination antiretroviral therapy (cART) remains challenging. One strategy has been using 3TC/ FTC monotherapy (3TC/FTC), which in the
Externí odkaz:
https://doaj.org/article/92e0356874504d5e835a250834f462a7
Autor:
Impaact P s Protocol Team, Kathryn Lypen, Violet Korutaro, Sybil G. Hosek, Benjamin Johnston, Deborah Kacanek, Mustafa E Ibrahim, K. Rivet Amico, Lynda Stranix-Chibanda, James F. Rooney, Nahida Chakhtoura, Hans M. L. Spiegel, Jenna Yager, Teacler Nematadzira, Clemensia Nakabiito, Lubbe Wiesner, Maysebole Masenya, Emily Brown, Sharon Huang, Peter L. Anderson, Benjamin H. Chi, Frank Taulo
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Intracellular tenofovir diphosphate (TFV-DP) concentration in dried blood spots (DBSs) is used to monitor cumulative pre-exposure prophylaxis (PrEP) adherence. We evaluated TFV-DP in DBSs following daily oral PrEP (emtricitabine 200 mg/ten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bb279a51a34952be76a84fc5d11eca7
https://doi.org/10.1093/cid/ciaa1872
https://doi.org/10.1093/cid/ciaa1872
Autor:
Carey Farquhar, Hans M. L. Spiegel, David Bukusi, Peter Maingi, Barbra A. Richardson, Peter Cherutich, Betsy Sambai, Marielle G Contesse, Felix Abuna, Paul Macharia, Anne Ng’ang’a, Beatrice Wamuti
Publikováno v:
Sexually Transmitted Diseases
A study of clients in cluster randomized trial in Kenya found that only two thirds of newly diagnosed human immunodeficiency virus (HIV)-positive and known HIV-positive sex partners not previously linked to care who received HIV assisted partner noti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84c529c86114468a557bf41fcf816e1f
https://doi.org/10.1097/olq.0000000000001222
https://doi.org/10.1097/olq.0000000000001222
Autor:
Rohan Hazra, Catherine M. Gordon, Hans M. L. Spiegel, Denise L. Jacobson, George K. Siberry, Jane C. Lindsey
Publikováno v:
Clin Infect Dis
No safety concerns were identified in a randomized, crossover study of alendronate/placebo in youth with perinatal HIV infection and low bone mineral density (BMD). BMD improved with 48 weeks of alendronate and continued to improve with an additional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::489c23f2970d0cc663233213b54d04e9
https://doi.org/10.1093/cid/ciaa861
https://doi.org/10.1093/cid/ciaa861
Autor:
Ian Mcgowan, Ross D Cranston, Kathryn Duffill, Aaron Siegel, Jarret C Engstrom, Alexyi Nikiforov, Cindy Jacobson, Khaja K Rehman, Julie Elliott, Elena Khanukhova, Kaleab Abebe, Christine Mauck, Hans M L Spiegel, Charlene S Dezzutti, Lisa C Rohan, Mark A Marzinke, Hiwot Hiruy, Craig W Hendrix, Nicola Richardson-Harman, Peter A Anton
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0125363 (2015)
The CHARM-01 study characterized the safety, acceptability, pharmacokinetics (PK), and pharmacodynamics (PD) of three tenofovir (TFV) gels for rectal application. The vaginal formulation (VF) gel was previously used in the CAPRISA 004 and VOICE vagin
Externí odkaz:
https://doaj.org/article/2b34f4f71e194ee9b4595419b03dbb92
Autor:
Hans M. L. Spiegel, Jane C. Lindsey, Rohan Hazra, Kathy George, Catherine M. Gordon, Jane E. Benson, George K. Siberry, Denise L. Jacobson, Aditya H. Gaur, Fabiana Rezende Amaral, Jesica Pagano-Therrien, Flávia Gomes Faleiro Ferreira
Publikováno v:
Clinical Infectious Diseases. 71:1281-1288
Background Children and adolescents with perinatal human immunodeficiency virus (HIV) infection and with low bone mineral density (BMD) may be at higher risk of osteoporosis and fractures in later life than their uninfected peers. Bisphosphonate ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4266f10cdcdef56b140038fbf865a265
https://doi.org/10.1093/cid/ciz957
https://doi.org/10.1093/cid/ciz957
Autor:
Kate M. Guthrie, Miles B. Brennan, Kevin J. Whaley, Tara Nyhuis, Karen T. Tashima, Thomas R. Moench, Deborah J. Anderson, Joseph A. Politch, Susan Cu-Uvin, Larry Zeitlin, Jai G Marathe, Kenneth H. Mayer, Hans M. L. Spiegel, Howard Cabral
Publikováno v:
PLoS Medicine, Vol 18, Iss 2, p e1003495 (2021)
PLoS Medicine
PLoS Medicine
Background MB66 film is a multipurpose prevention technology (MPT) product with monoclonal antibodies (mAbs) against HIV-1 (VRC01-N) and HSV-1 and 2 (HSV8-N). The mAbs were produced by transient expression in Nicotiana benthamiana (N). We conducted a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16cfffd83bcc7837a8d8aa3adbd2bc94
https://doaj.org/article/080a0cd6780b4946ae5836420c4ae97a
https://doaj.org/article/080a0cd6780b4946ae5836420c4ae97a